Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Feb;9(2):409-414.
doi: 10.21037/tcr.2019.12.82.

Long-term survivors with immunotherapy in advanced NSCLC: is 'cure' within reach?

Sara Monteverdi  1 , Emanuele Vita  2 , Giulia Sartori  1 , Miriam Grazia Ferrara  2 , Ettore D'Argento  3 , Giampaolo Tortora  2   3 , Michele Milella  1 , Emilio Bria #  2   3 , Sara Pilotto #  1
Affiliations
Editorial

Long-term survivors with immunotherapy in advanced NSCLC: is 'cure' within reach?

Sara Monteverdi et al. Transl Cancer Res. 2020 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2019.12.82). Michele Milella reports personal fees from Pfizer, EUSA Pharma and Astra Zeneca. Emilio Bria received honoraria or speakers’ fee from MSD, Astra-Zeneca, Celgene, Pfizer, Helsinn, Eli-Lilly, BMS, Novartis and Roche. Sara Pilotto received honoraria or speakers’ fee from Astra-Zeneca, Eli-Lilly, BMS, Boehringer Ingelheim, MSD, Roche and Istituto Gentili. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol 2019;37:2518-27. 10.1200/JCO.19.00934 - DOI - PMC - PubMed
    1. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-28. 10.1056/NEJMoa1501824 - DOI - PubMed
    1. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823-33. 10.1056/NEJMoa1606774 - DOI - PubMed
    1. Reck M, Rodríguez-Abreu D, Robinson AG, et al. OA14. 01 KEYNOTE-024 3-year survival update: pembrolizumab vs platinum-based chemotherapy for advanced non-small-cell lung cancer. J Thorac Oncol 2019;14:S243. 10.1016/j.jtho.2019.08.483 - DOI - PubMed
    1. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 2019;393:1819-30. 10.1016/S0140-6736(18)32409-7 - DOI - PubMed